Compare Medtronic PLC (MDT) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Snap Inc — how do they compare? Medtronic PLC trades at $87.75 (market cap $112.24B), while Snap Inc trades at $5.96 (market cap $9.83B). The key difference: Medtronic PLC is far larger — about 11.4× Snap Inc's market cap, and Medtronic PLC pays a 3.28% dividend while Snap Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Snap Inc for 68 Days on average.
| MDT | SNAP | |
|---|---|---|
Market Cap | $112.24B | $9.83B |
Volume | 105,663,236 | 28,532,342 |
Sector | Health | Media |
52-Week High | $105.35 | $9.09 |
52-Week Low | $73.75 | $3.93 |
Typical Hold Time | 63 Days | 68 Days |
Enterprise Value | $131.58B | $11.39B |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
SNAP trades at $5.81, up 0.17% on the day, with a bullish technical signal from moving averages. The company reported revenue of $5.93B in 2025, with a net loss narrowing to -$460M, improving its profit margin to -7.77%. Recent news highlights Snap's push into enterprise AR glasses with NVIDIA and Salesforce partnerships, driving investor optimism.
The outlook remains cautious as SNAP continues to post losses despite revenue growth. Analyst consensus is a 'Hold' with a $7.78 price target, suggesting modest upside. Key risks include intense competition, regulatory pressures, and the challenge of achieving profitability. The stock's valuation appears stretched with a high EV/EBITDA of 1,149.99.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
